MovDisordV3, PascalFrancis, Corpus, bibRecord, 000389

Wearing-Off Scales in Parkinson's Disease: Critique and Recommendations

Identifieur interne : 000389 ( PascalFrancis/Corpus ); précédent : 000388; suivant : 000390

Wearing-Off Scales in Parkinson's Disease: Critique and Recommendations

Auteurs : Angelo Antonini ; Pablo Martinez-Martin ; Ray K. Chaudhuri ; Marcelo Merello ; Robert Hauser ; Regina Katzenschlager ; Per Odin ; Mark Stacy ; Fabrizio Stocchi ; Werner Poewe ; Oliver Rascol ; Cristina Sampaio ; Anette Schrag ; Glennt. Stebbins ; Christopher G. Goetz

Source :

Movement disorders [ 0885-3185 ] ; 2011.

RBID : Pascal:11-0481571

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Recommandation, Psychométrie, Validité, Fiabilité.

English descriptors

KwdEn :
- Nervous system diseases, Parkinson disease, Psychometrics, Recommendation, Reliability, Validity.

Abstract

Wearing-off occurs in the majority of patients with Parkinson's disease after a few years of dopaminergic therapy. Because a variety of scales have been used to estimate wearing-off, the Movement Disorder Society commissioned a task force to assess their clinimetric properties. A systematic review was conducted to identify wearing-off scales that have either been validated or used in Parkinson's patients. A scale was designated "Recommended" if it had been used in clinical studies beyond the group that developed it, if it had been specifically used in Parkinson's disease reports, and if clinimetric studies had established that it is valid, reliable, and sensitive. "Suggested" scales met 2 of the above criteria, and those meeting 1 were "Listed." We identified 3 diagnostic and 4 severity rating scales for wearing-off quantification. Two questionnaires met the criteria to be Recommended for diagnostic screening (questionnaires for 19 and 9 items), and 1 was Suggested (questionnaire for 32 items). Only the patient diaries were Recommended to assess wearing-off severity, with the caveat of relatively limited knowledge of validity. Among the other severity assessment tools, the Unified Parkinson Disease Rating Scale version 3 and the version revised from the Movement Disorders Society were classified as Suggested, whereas the Treatment Response Scale was Listed.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 26`
A06				`@2 12`
A08	`01`	`1`	`ENG`	`@1 Wearing-Off Scales in Parkinson's Disease: Critique and Recommendations`
A11	`01`	`1`		`@1 ANTONINI (Angelo)`
A11	`02`	`1`		`@1 MARTINEZ-MARTIN (Pablo)`
A11	`03`	`1`		`@1 CHAUDHURI (Ray K.)`
A11	`04`	`1`		`@1 MERELLO (Marcelo)`
A11	`05`	`1`		`@1 HAUSER (Robert)`
A11	`06`	`1`		`@1 KATZENSCHLAGER (Regina)`
A11	`07`	`1`		`@1 ODIN (Per)`
A11	`08`	`1`		`@1 STACY (Mark)`
A11	`09`	`1`		`@1 STOCCHI (Fabrizio)`
A11	`10`	`1`		`@1 POEWE (Werner)`
A11	`11`	`1`		`@1 RASCOL (Oliver)`
A11	`12`	`1`		`@1 SAMPAIO (Cristina)`
A11	`13`	`1`		`@1 SCHRAG (Anette)`
A11	`14`	`1`		`@1 STEBBINS (GlennT.)`
A11	`15`	`1`		`@1 GOETZ (Christopher G.)`
A14	`01`			`@1 Department for Parkinson's Disease and Movement Disorders, IRCCS "San Camillo @2 Venice @3 ITA @Z 1 aut.`
A14	`02`			`@1 Area of Applied Epidemiology. National Center for Epidemiology and CIBERNED, Carlos III Institute of Health @2 Madrid @3 ESP @Z 2 aut.`
A14	`03`			`@1 National Parkinson Foundation Centre of Excellence, Kings College and Institute of Psychiatry @2 London @3 GBR @Z 3 aut.`
A14	`04`			`@1 Movement Disorders Section. FLENI @2 Buenos Aires @3 ARG @Z 4 aut.`
A14	`05`			`@1 Department of Neurology, University of South Florida @2 Tampa, Florida @3 USA @Z 5 aut.`
A14	`06`			`@1 Department of Neurology, Danube Hospital/SMZ-Ost @2 Vienna @3 AUT @Z 6 aut.`
A14	`07`			`@1 Department of Neurology, Central Hospital @2 Bremerhaven @3 DEU @Z 7 aut.`
A14	`08`			`@1 Duke University Medical Center @2 Durham, North Carolina @3 USA @Z 8 aut.`
A14	`09`			`@1 Institute of Neurology, IRCCS "San Raffaele @2 Rome @3 ITA @Z 9 aut.`
A14	`10`			`@1 Department of Neurology, University Hospital @2 Innsbruck @3 AUT @Z 10 aut.`
A14	`11`			`@1 Laboratoire de Pharmacologie Medicale et Clinique @2 Toulouse @3 FRA @Z 11 aut.`
A14	`12`			`@1 Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine @2 Lisbon @3 PRT @Z 12 aut.`
A14	`13`			`@1 Department of Clinical Neurosciences, Institute of Neurology, University College London @2 London @3 GBR @Z 13 aut.`
A14	`14`			`@1 Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine @2 Atlanta, Georgia @3 USA @Z 14 aut.`
A14	`15`			`@1 Department of Neurological Services, Rush University Medical Center @2 Chicago, Illinois @3 USA @Z 15 aut.`
A20				`@1 2169-2175`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000505557630050`
A44				`@0 0000 @1 © 2011 INIST-CNRS. All rights reserved.`
A45				`@0 39 ref.`
A47	`01`	`1`		`@0 11-0481571`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Wearing-off occurs in the majority of patients with Parkinson's disease after a few years of dopaminergic therapy. Because a variety of scales have been used to estimate wearing-off, the Movement Disorder Society commissioned a task force to assess their clinimetric properties. A systematic review was conducted to identify wearing-off scales that have either been validated or used in Parkinson's patients. A scale was designated "Recommended" if it had been used in clinical studies beyond the group that developed it, if it had been specifically used in Parkinson's disease reports, and if clinimetric studies had established that it is valid, reliable, and sensitive. "Suggested" scales met 2 of the above criteria, and those meeting 1 were "Listed." We identified 3 diagnostic and 4 severity rating scales for wearing-off quantification. Two questionnaires met the criteria to be Recommended for diagnostic screening (questionnaires for 19 and 9 items), and 1 was Suggested (questionnaire for 32 items). Only the patient diaries were Recommended to assess wearing-off severity, with the caveat of relatively limited knowledge of validity. Among the other severity assessment tools, the Unified Parkinson Disease Rating Scale version 3 and the version revised from the Movement Disorders Society were classified as Suggested, whereas the Treatment Response Scale was Listed.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Recommandation @5 09`
C03	`03`	`X`	`ENG`	`@0 Recommendation @5 09`
C03	`03`	`X`	`SPA`	`@0 Recomendación @5 09`
C03	`04`	`X`	`FRE`	`@0 Psychométrie @5 10`
C03	`04`	`X`	`ENG`	`@0 Psychometrics @5 10`
C03	`04`	`X`	`SPA`	`@0 Psicometría @5 10`
C03	`05`	`X`	`FRE`	`@0 Validité @5 11`
C03	`05`	`X`	`ENG`	`@0 Validity @5 11`
C03	`05`	`X`	`SPA`	`@0 Validez @5 11`
C03	`06`	`X`	`FRE`	`@0 Fiabilité @5 12`
C03	`06`	`X`	`ENG`	`@0 Reliability @5 12`
C03	`06`	`X`	`SPA`	`@0 Fiabilidad @5 12`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 332`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 11-0481571 INIST
ET :	Wearing-Off Scales in Parkinson's Disease: Critique and Recommendations
AU :	ANTONINI (Angelo); MARTINEZ-MARTIN (Pablo); CHAUDHURI (Ray K.); MERELLO (Marcelo); HAUSER (Robert); KATZENSCHLAGER (Regina); ODIN (Per); STACY (Mark); STOCCHI (Fabrizio); POEWE (Werner); RASCOL (Oliver); SAMPAIO (Cristina); SCHRAG (Anette); STEBBINS (GlennT.); GOETZ (Christopher G.)
AF :	Department for Parkinson's Disease and Movement Disorders, IRCCS "San Camillo/Venice/Italie (1 aut.); Area of Applied Epidemiology. National Center for Epidemiology and CIBERNED, Carlos III Institute of Health/Madrid/Espagne (2 aut.); National Parkinson Foundation Centre of Excellence, Kings College and Institute of Psychiatry/London/Royaume-Uni (3 aut.); Movement Disorders Section. FLENI/Buenos Aires/Argentine (4 aut.); Department of Neurology, University of South Florida/Tampa, Florida/Etats-Unis (5 aut.); Department of Neurology, Danube Hospital/SMZ-Ost/Vienna/Autriche (6 aut.); Department of Neurology, Central Hospital/Bremerhaven/Allemagne (7 aut.); Duke University Medical Center/Durham, North Carolina/Etats-Unis (8 aut.); Institute of Neurology, IRCCS "San Raffaele/Rome/Italie (9 aut.); Department of Neurology, University Hospital/Innsbruck/Autriche (10 aut.); Laboratoire de Pharmacologie Medicale et Clinique/Toulouse/France (11 aut.); Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine/Lisbon/Portugal (12 aut.); Department of Clinical Neurosciences, Institute of Neurology, University College London/London/Royaume-Uni (13 aut.); Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine/Atlanta, Georgia/Etats-Unis (14 aut.); Department of Neurological Services, Rush University Medical Center/Chicago, Illinois/Etats-Unis (15 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2011; Vol. 26; No. 12; Pp. 2169-2175; Bibl. 39 ref.
LA :	Anglais
EA :	Wearing-off occurs in the majority of patients with Parkinson's disease after a few years of dopaminergic therapy. Because a variety of scales have been used to estimate wearing-off, the Movement Disorder Society commissioned a task force to assess their clinimetric properties. A systematic review was conducted to identify wearing-off scales that have either been validated or used in Parkinson's patients. A scale was designated "Recommended" if it had been used in clinical studies beyond the group that developed it, if it had been specifically used in Parkinson's disease reports, and if clinimetric studies had established that it is valid, reliable, and sensitive. "Suggested" scales met 2 of the above criteria, and those meeting 1 were "Listed." We identified 3 diagnostic and 4 severity rating scales for wearing-off quantification. Two questionnaires met the criteria to be Recommended for diagnostic screening (questionnaires for 19 and 9 items), and 1 was Suggested (questionnaire for 32 items). Only the patient diaries were Recommended to assess wearing-off severity, with the caveat of relatively limited knowledge of validity. Among the other severity assessment tools, the Unified Parkinson Disease Rating Scale version 3 and the version revised from the Movement Disorders Society were classified as Suggested, whereas the Treatment Response Scale was Listed.
CC :	002B17; 002B17G
FD :	Maladie de Parkinson; Pathologie du système nerveux; Recommandation; Psychométrie; Validité; Fiabilité
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Parkinson disease; Nervous system diseases; Recommendation; Psychometrics; Validity; Reliability
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Parkinson enfermedad; Sistema nervioso patología; Recomendación; Psicometría; Validez; Fiabilidad
LO :	INIST-20953.354000505557630050
ID :	11-0481571

Links to Exploration step

Pascal:11-0481571

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Wearing-Off Scales in Parkinson's Disease: Critique and Recommendations</title>
<author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name>
<affiliation><inist:fA14 i1="01"><s1>Department for Parkinson's Disease and Movement Disorders, IRCCS "San Camillo</s1>
<s2>Venice</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation><inist:fA14 i1="02"><s1>Area of Applied Epidemiology. National Center for Epidemiology and CIBERNED, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chaudhuri, Ray K" sort="Chaudhuri, Ray K" uniqKey="Chaudhuri R" first="Ray K." last="Chaudhuri">Ray K. Chaudhuri</name>
<affiliation><inist:fA14 i1="03"><s1>National Parkinson Foundation Centre of Excellence, Kings College and Institute of Psychiatry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Merello, Marcelo" sort="Merello, Marcelo" uniqKey="Merello M" first="Marcelo" last="Merello">Marcelo Merello</name>
<affiliation><inist:fA14 i1="04"><s1>Movement Disorders Section. FLENI</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert" sort="Hauser, Robert" uniqKey="Hauser R" first="Robert" last="Hauser">Robert Hauser</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Neurology, Danube Hospital/SMZ-Ost</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Odin, Per" sort="Odin, Per" uniqKey="Odin P" first="Per" last="Odin">Per Odin</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurology, Central Hospital</s1>
<s2>Bremerhaven</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
<affiliation><inist:fA14 i1="08"><s1>Duke University Medical Center</s1>
<s2>Durham, North Carolina</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name>
<affiliation><inist:fA14 i1="09"><s1>Institute of Neurology, IRCCS "San Raffaele</s1>
<s2>Rome</s2>
<s3>ITA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation><inist:fA14 i1="10"><s1>Department of Neurology, University Hospital</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Oliver Rascol</name>
<affiliation><inist:fA14 i1="11"><s1>Laboratoire de Pharmacologie Medicale et Clinique</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation><inist:fA14 i1="12"><s1>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
<affiliation><inist:fA14 i1="13"><s1>Department of Clinical Neurosciences, Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stebbins, Glennt" sort="Stebbins, Glennt" uniqKey="Stebbins G" first="Glennt." last="Stebbins">Glennt. Stebbins</name>
<affiliation><inist:fA14 i1="14"><s1>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation><inist:fA14 i1="15"><s1>Department of Neurological Services, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0481571</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0481571 INIST</idno>
<idno type="RBID">Pascal:11-0481571</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000389</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Wearing-Off Scales in Parkinson's Disease: Critique and Recommendations</title>
<author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name>
<affiliation><inist:fA14 i1="01"><s1>Department for Parkinson's Disease and Movement Disorders, IRCCS "San Camillo</s1>
<s2>Venice</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation><inist:fA14 i1="02"><s1>Area of Applied Epidemiology. National Center for Epidemiology and CIBERNED, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chaudhuri, Ray K" sort="Chaudhuri, Ray K" uniqKey="Chaudhuri R" first="Ray K." last="Chaudhuri">Ray K. Chaudhuri</name>
<affiliation><inist:fA14 i1="03"><s1>National Parkinson Foundation Centre of Excellence, Kings College and Institute of Psychiatry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Merello, Marcelo" sort="Merello, Marcelo" uniqKey="Merello M" first="Marcelo" last="Merello">Marcelo Merello</name>
<affiliation><inist:fA14 i1="04"><s1>Movement Disorders Section. FLENI</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert" sort="Hauser, Robert" uniqKey="Hauser R" first="Robert" last="Hauser">Robert Hauser</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Neurology, Danube Hospital/SMZ-Ost</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Odin, Per" sort="Odin, Per" uniqKey="Odin P" first="Per" last="Odin">Per Odin</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurology, Central Hospital</s1>
<s2>Bremerhaven</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
<affiliation><inist:fA14 i1="08"><s1>Duke University Medical Center</s1>
<s2>Durham, North Carolina</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name>
<affiliation><inist:fA14 i1="09"><s1>Institute of Neurology, IRCCS "San Raffaele</s1>
<s2>Rome</s2>
<s3>ITA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation><inist:fA14 i1="10"><s1>Department of Neurology, University Hospital</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Oliver Rascol</name>
<affiliation><inist:fA14 i1="11"><s1>Laboratoire de Pharmacologie Medicale et Clinique</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation><inist:fA14 i1="12"><s1>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
<affiliation><inist:fA14 i1="13"><s1>Department of Clinical Neurosciences, Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stebbins, Glennt" sort="Stebbins, Glennt" uniqKey="Stebbins G" first="Glennt." last="Stebbins">Glennt. Stebbins</name>
<affiliation><inist:fA14 i1="14"><s1>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation><inist:fA14 i1="15"><s1>Department of Neurological Services, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Psychometrics</term>
<term>Recommendation</term>
<term>Reliability</term>
<term>Validity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Recommandation</term>
<term>Psychométrie</term>
<term>Validité</term>
<term>Fiabilité</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Wearing-off occurs in the majority of patients with Parkinson's disease after a few years of dopaminergic therapy. Because a variety of scales have been used to estimate wearing-off, the Movement Disorder Society commissioned a task force to assess their clinimetric properties. A systematic review was conducted to identify wearing-off scales that have either been validated or used in Parkinson's patients. A scale was designated "Recommended" if it had been used in clinical studies beyond the group that developed it, if it had been specifically used in Parkinson's disease reports, and if clinimetric studies had established that it is valid, reliable, and sensitive. "Suggested" scales met 2 of the above criteria, and those meeting 1 were "Listed." We identified 3 diagnostic and 4 severity rating scales for wearing-off quantification. Two questionnaires met the criteria to be Recommended for diagnostic screening (questionnaires for 19 and 9 items), and 1 was Suggested (questionnaire for 32 items). Only the patient diaries were Recommended to assess wearing-off severity, with the caveat of relatively limited knowledge of validity. Among the other severity assessment tools, the Unified Parkinson Disease Rating Scale version 3 and the version revised from the Movement Disorders Society were classified as Suggested, whereas the Treatment Response Scale was Listed.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>26</s2>
</fA05>
<fA06><s2>12</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Wearing-Off Scales in Parkinson's Disease: Critique and Recommendations</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ANTONINI (Angelo)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MARTINEZ-MARTIN (Pablo)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CHAUDHURI (Ray K.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>MERELLO (Marcelo)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>HAUSER (Robert)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>KATZENSCHLAGER (Regina)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>ODIN (Per)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>STACY (Mark)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>STOCCHI (Fabrizio)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>POEWE (Werner)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>RASCOL (Oliver)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>SAMPAIO (Cristina)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>SCHRAG (Anette)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>STEBBINS (GlennT.)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>GOETZ (Christopher G.)</s1>
</fA11>
<fA14 i1="01"><s1>Department for Parkinson's Disease and Movement Disorders, IRCCS "San Camillo</s1>
<s2>Venice</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Area of Applied Epidemiology. National Center for Epidemiology and CIBERNED, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>National Parkinson Foundation Centre of Excellence, Kings College and Institute of Psychiatry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Movement Disorders Section. FLENI</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurology, University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Neurology, Danube Hospital/SMZ-Ost</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Neurology, Central Hospital</s1>
<s2>Bremerhaven</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Duke University Medical Center</s1>
<s2>Durham, North Carolina</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Institute of Neurology, IRCCS "San Raffaele</s1>
<s2>Rome</s2>
<s3>ITA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Department of Neurology, University Hospital</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Laboratoire de Pharmacologie Medicale et Clinique</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="13"><s1>Department of Clinical Neurosciences, Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="14"><s1>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="15"><s1>Department of Neurological Services, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA20><s1>2169-2175</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000505557630050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>39 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0481571</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Wearing-off occurs in the majority of patients with Parkinson's disease after a few years of dopaminergic therapy. Because a variety of scales have been used to estimate wearing-off, the Movement Disorder Society commissioned a task force to assess their clinimetric properties. A systematic review was conducted to identify wearing-off scales that have either been validated or used in Parkinson's patients. A scale was designated "Recommended" if it had been used in clinical studies beyond the group that developed it, if it had been specifically used in Parkinson's disease reports, and if clinimetric studies had established that it is valid, reliable, and sensitive. "Suggested" scales met 2 of the above criteria, and those meeting 1 were "Listed." We identified 3 diagnostic and 4 severity rating scales for wearing-off quantification. Two questionnaires met the criteria to be Recommended for diagnostic screening (questionnaires for 19 and 9 items), and 1 was Suggested (questionnaire for 32 items). Only the patient diaries were Recommended to assess wearing-off severity, with the caveat of relatively limited knowledge of validity. Among the other severity assessment tools, the Unified Parkinson Disease Rating Scale version 3 and the version revised from the Movement Disorders Society were classified as Suggested, whereas the Treatment Response Scale was Listed.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Recommandation</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Recommendation</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Recomendación</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Psychométrie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Psychometrics</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Psicometría</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Validité</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Validity</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Validez</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Fiabilité</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Reliability</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Fiabilidad</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>332</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 11-0481571 INIST</NO>
<ET>Wearing-Off Scales in Parkinson's Disease: Critique and Recommendations</ET>
<AU>ANTONINI (Angelo); MARTINEZ-MARTIN (Pablo); CHAUDHURI (Ray K.); MERELLO (Marcelo); HAUSER (Robert); KATZENSCHLAGER (Regina); ODIN (Per); STACY (Mark); STOCCHI (Fabrizio); POEWE (Werner); RASCOL (Oliver); SAMPAIO (Cristina); SCHRAG (Anette); STEBBINS (GlennT.); GOETZ (Christopher G.)</AU>
<AF>Department for Parkinson's Disease and Movement Disorders, IRCCS "San Camillo/Venice/Italie (1 aut.); Area of Applied Epidemiology. National Center for Epidemiology and CIBERNED, Carlos III Institute of Health/Madrid/Espagne (2 aut.); National Parkinson Foundation Centre of Excellence, Kings College and Institute of Psychiatry/London/Royaume-Uni (3 aut.); Movement Disorders Section. FLENI/Buenos Aires/Argentine (4 aut.); Department of Neurology, University of South Florida/Tampa, Florida/Etats-Unis (5 aut.); Department of Neurology, Danube Hospital/SMZ-Ost/Vienna/Autriche (6 aut.); Department of Neurology, Central Hospital/Bremerhaven/Allemagne (7 aut.); Duke University Medical Center/Durham, North Carolina/Etats-Unis (8 aut.); Institute of Neurology, IRCCS "San Raffaele/Rome/Italie (9 aut.); Department of Neurology, University Hospital/Innsbruck/Autriche (10 aut.); Laboratoire de Pharmacologie Medicale et Clinique/Toulouse/France (11 aut.); Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine/Lisbon/Portugal (12 aut.); Department of Clinical Neurosciences, Institute of Neurology, University College London/London/Royaume-Uni (13 aut.); Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine/Atlanta, Georgia/Etats-Unis (14 aut.); Department of Neurological Services, Rush University Medical Center/Chicago, Illinois/Etats-Unis (15 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2011; Vol. 26; No. 12; Pp. 2169-2175; Bibl. 39 ref.</SO>
<LA>Anglais</LA>
<EA>Wearing-off occurs in the majority of patients with Parkinson's disease after a few years of dopaminergic therapy. Because a variety of scales have been used to estimate wearing-off, the Movement Disorder Society commissioned a task force to assess their clinimetric properties. A systematic review was conducted to identify wearing-off scales that have either been validated or used in Parkinson's patients. A scale was designated "Recommended" if it had been used in clinical studies beyond the group that developed it, if it had been specifically used in Parkinson's disease reports, and if clinimetric studies had established that it is valid, reliable, and sensitive. "Suggested" scales met 2 of the above criteria, and those meeting 1 were "Listed." We identified 3 diagnostic and 4 severity rating scales for wearing-off quantification. Two questionnaires met the criteria to be Recommended for diagnostic screening (questionnaires for 19 and 9 items), and 1 was Suggested (questionnaire for 32 items). Only the patient diaries were Recommended to assess wearing-off severity, with the caveat of relatively limited knowledge of validity. Among the other severity assessment tools, the Unified Parkinson Disease Rating Scale version 3 and the version revised from the Movement Disorders Society were classified as Suggested, whereas the Treatment Response Scale was Listed.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Pathologie du   système nerveux; Recommandation; Psychométrie; Validité; Fiabilité</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Parkinson disease; Nervous system diseases; Recommendation; Psychometrics; Validity; Reliability</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Parkinson enfermedad; Sistema nervioso patología; Recomendación; Psicometría; Validez; Fiabilidad</SD>
<LO>INIST-20953.354000505557630050</LO>
<ID>11-0481571</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000389 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000389 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:11-0481571
   |texte=   Wearing-Off Scales in Parkinson's Disease: Critique and Recommendations
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Wearing-Off Scales in Parkinson's Disease: Critique and Recommendations

Wearing-Off Scales in Parkinson's Disease: Critique and Recommendations

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri